Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Presented on .

An estimated 50,000 individuals become infected with the human immunodeficiency virus (HIV) in the United States annually. A new prevention strategy, Pre-exposure Prophylaxis (PrEP), is intended for high-risk populations to reduce their risk of becoming infected with HIV. PrEP includes daily medication and routine follow-up. When used consistently, PrEP is shown to reduce the risk of HIV infection. If delivered effectively and used in combination with other proven prevention methods, PrEP may play a significant role in helping to address the HIV epidemic in the United States.

This session of Grand Rounds explored the opportunities for using PrEP as another tool to prevent the transmission of HIV and discuss the challenges to effective implementation that must be addressed to make PrEP a success.

Beyond the Data

Dr. John Iskander sits down with Dr. Dawn Smith and Dr. Melanie Thompson to discuss Pre-Exposure Prophylaxis (PrEP) as an HIV prevention tool. When taken consistently, PrEP has been shown to reduce the risk of HIV infection by up to 92%.

Patients should know that:

  • PrEP is very well tolerated
  • No serious side effects were observed
  • When taken as directed, PrEP is effective

Practitioners should be aware that:

  • PrEP is approved for use in populations with substantial risk of ongoing exposure
  • Several resources are available to aid in learning about and prescribing PrEP
  • Talking to patients about medication adherence and risk reduction is key to efficacy

Presented By

Walid Heneine, Phd
Team Lead, Surveillance, Antiretroviral Prophylaxis and Drug Resistance, Laboratory Branch, Division of HIV/AIDS Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC
Melanie Thompson, MD
Founder and Principal Investigator
AIDS Research Consortium of Atlanta
Dawn K. Smith, MD, MPH, MS
Biomedical Interventions Activity Lead, Prevention with Negatives Team,
Division of HIV/AIDS Prevention

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC
Jonathan Mermin, MD, MPH
Director
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC

Facilitated By

John Iskander, MD, MPH
Scientific Director
Phoebe Thorpe, MD, MPH
Deputy Scientific Director
Susan Laird, MSN, RN
Communications Director

Enjoyed this Presentation?

Get notified about the latest updates from Public Health Grand Rounds right in your inbox by setting up an alert today!

Get notified about the latest updates from Public Health Grand Rounds right in your inbox by setting up an alert today!Sign Up

Sign Up

Get notified about the latest updates from Public Health Grand Rounds right in your inbox by setting up an alert today!

You May Also Like

HIV Prevention

August 2012, HIV/STD/TB
Doctor and patient

The incidence of HIV is stable, and effective treatment exists to prevent illness and death. Over 1.1 million people are living with HIV. The growing number with the potential to transmit HIV presents a challenge for prevention. Learn about new directions in monitoring the burden of HIV and resource allocation.

Unsafe Injection Practices

November 2012, Hospital Healthcare
Syringe  inserted into bottle

Injectable medicines are used to prevent, diagnosis, and treat various illnesses. Unsafe injection practices in various healthcare settings put patients at risk of infection. Find out how these harms are preventable through renewed attention to infection control and injection safety practices.

  • Page last reviewed: February 28, 2018
  • Page last updated: February 28, 2018
  • Content source:
    • Office of the Associate Director for Science
    • Page maintained by: Office of the Associate Director for Communication
TOP